CEA (carcinoembryonic antigen): Its role as a marker in the management of cancer

Goldenberg, D. M.; Neville, A. Munro; Carter, A. C.; Go, Vay Liang W.; Ed, Holyoke; Isselbacher, K. J.; Schein, Philip S.; Schwartz, Morton K.

doi:10.1007/bf00410109

Cited by 66 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an earlier study, we coupled p-[1,2-dicarba-closo- [ (10), and found that boron labeling did not destroy the immunoreactivity of the antibodies labeled with eight carborane cages or less (11). It was the objective of the current study to assess the tumorlocalizing capabilities of such boron-conjugated antibodies against CEA.…”

mentioning

confidence: 89%

Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system.

Goldenberg¹,

Rm²,

Primus³

et al. 1984

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 89%

Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system.

Goldenberg¹,

Rm²,

Primus³

et al. 1984

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Development of sensitive, specific immunoassays to detect circulating tumor-shed antigens can assist in the early detection of the disease, at a stage more likely to yield to therapeutic procedures (Goldenberg et a/., 1981;Chu, 1990). Radiolabeled antibodies have been shown to be of considerable value for the clinical localization of tumor masses (Colcher et a/., 1987;Goldenberg et al, 1989).…”

mentioning

confidence: 98%

Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin

Gold

Lew

Maliniak

et al. 1994

Intl Journal of Cancer

View full text Add to dashboard Cite

A monoclonal antibody (MAb), PAM4, having reactivity with pancreatic carcinoma has been developed. PAM4 is an IgG1 immunoglobulin produced by immunization of mice with mucin purified from the xenografted RIP1 human pancreatic carcinoma. An immunohistochemical study of normal adult tissues showed the PAM4 reactive epitope to be restricted to the gastrointestinal tract and absent from normal pancreas. In neoplastic tissue, PAM4 was reactive with 85% of the pancreatic carcinomas, approximately half of the colon cancers and none of the breast, ovarian, prostate, renal and liver cancers. PAM4 was, in general, non-reactive with pancreatitis specimens whereas CA19.9 and DUPAN2 were strongly reactive with each one. Treatment of the mucin antigen by heating, reduction of disulfide bonds, or protease digestion abolished immunoreactivity with PAM4. Treatment of the mucin by neuraminidase or periodate oxidation reduced immunoreactivity but did not completely abolish it. Our data are consistent with the proposal that the PAM4 epitope is a conformationally dependent peptide epitope and that certain carbohydrate structures are necessary in order to maintain the correct peptide conformation. The high specificity and intense reactivity of PAM4 with pancreatic carcinoma tissue suggests that the antibody may prove useful for in vitro diagnostic assays as well as in vivo targeting of diagnostic and therapeutic agents.

show abstract

“…Tumour antigen levels have been used for many years in the clinical management of cancer (Goldenberg et al, 1981). They have proved of value in detecting recurrent disease (NIH Consensus Statement, 1981;Hida et al, 1996), monitoring the effects of chemotherapy and predicting prolonged survival (Hine and Dykes, 1984;AllenMersh et al, 1987;Ward et al, 1993).…”

mentioning

confidence: 99%

Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA

et al. 1999

View full text Add to dashboard Cite

Summary Inhibition of matrix metalloproteinases (MMPs) is an attractive approach to adjuvant therapy in the treatment of cancer. Marimastat is the first orally administered, synthetic MMP inhibitor to be evaluated, in this capacity, in the clinic. Measurement of the rate of change of circulating tumour antigens was used for evaluating biological activity and defining optimum dosage in the early clinical trials of marimastat. Although tumour antigen levels have been used in the clinical management of cancer for many years, they have not been validated as markers of disease progression. In order to investigate the relationship between the effects of marimastat on tumour growth and circulating tumour antigen levels, mice bearing the human gastric tumour, MGLVA1, were treated with marimastat. The MMP inhibitor exerted a significant therapeutic effect, reducing tumour growth rate by 48% (P = 0.0005), and increasing median survival from 19 to 30 days (P = 0.0001). In addition, carcinoembryonic antigen (CEA) levels were measured in serum samples from animals sacrificed at regular intervals, and correlated with excised tumour weight. It was shown that the natural log of the CEA concentration was linearly related to the natural log of the tumour weight and that treatment was not a significant factor in this relationship (P = 0.7). In conclusion, circulating CEA levels were not directly affected by marimastat, but did reflect tumour size. These results support the use of cancer antigens as markers of biological activity in early phase trials of non-cytotoxic anticancer agents.

show abstract

CEA (carcinoembryonic antigen): Its role as a marker in the management of cancer

Cited by 66 publications

References 0 publications

Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system.

Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system.

Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin

Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA

Contact Info

Product

Resources

About